Pharmaceuticals, Biotechnology & Life Sciences

Unicycive Therapeutics faces a critical juncture after a director’s resignation and volatile stock, prompting investors to scrutinize its financial health and kidney‑disease therapy pipeline for sustainable growth.

VG Life Sciences Inc. develops breakthrough therapies for cancer, infectious and autoimmune diseases, offering investors insight into its biotech innovation and market potential.

Invest in Simply Solventless Concentrates Ltd. – a Canadian cannabis firm focused on premium solventless concentrates, low P/E, volatile yet promising growth.

Regencell Bioscience’s new drilling shows a 179‑m copper‑equivalent grade of 1.5%, confirming a large Cu‑Au‑Ag system and boosting its mining potential while it stays focused on innovative neurocognitive medicine.

Explore Terns Pharmaceuticals, a Nasdaq biopharma leader targeting liver disease and cancer, its volatile stock, growth, and innovative therapies.

Shionogi & Co. partners with Virchow Laboratories to secure high‑purity components for sulfamethoxazole, highlighting strategic supply‑chain alliances and the risks they pose to the pharma industry.

bioAffinity Technologies Inc. pioneers non‑invasive cancer diagnostics and therapeutics—discover its biotech innovations, stock trends, and future potential.

Evaxion’s phase‑2 trial extension shows a 75% objective response rate and 92% durable benefit for its AI‑driven melanoma vaccine EVX‑01, promising strong monotherapy and combination efficacy.

TransCode Therapeutics leads biotech with a proprietary delivery system that targets genetic tumors and metastases, promising safer, personalized cancer treatments and investor growth potential.

Chimin Health Management: China’s IV solution leader facing volatility yet poised for growth through eco‑friendly packaging.